Tagged with research

UK US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central London, with plans to open the ‘London Discovery Research Centre’ by 2025.   Having announced that the hub would be built in 2017, one year after the UK’s vote…

Japan Ryu Ogawa and Satoshi Tamaki of Japanese AI-powered drug discovery firm Molcure outline how their technology can supercharge the speed and efficiency of the drug discovery process as well as the wider implications for greater use of artificial intelligence in the biotechnology field.   The greatest strength of Molcure’s system…

Belgium Belgian doctor, researcher and professor, Stéphane De Wit has been with the St Pierre University Hospital in Brussels since 1983. Initially planning to specialize in intensive care, his first internship took him by chance to the infectious diseases department where he encountered his first patients with AIDS, met his mentor,…

Boehringer Ingelheim With its brand new hub in Shanghai dedicated to research, business development and venture funding, German pharma giant Boehringer Ingelheim is taking a step further toward accessing innovation from the Chinese biotech industry.   Boehringer Ingelheim has its sights set on establishing a deeper rapport with the Chinese biotech sector.…

China Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the potential to significantly increase success rates in early drug discovery, and the next steps for the company’s expansion.   By now, we have a platform of over 500…

UK Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical industry’s rapid response to COVID-19 and the three ways in which the sector is driving national innovation forwards.   With the upheaval of recent months, businesses up and down the UK have been forced to adapt…

AMR June 9th 2020 saw the launch of a new action fund on antimicrobial resistance (AMR), with 23 leading biopharmaceutical companies committing to almost USD one billion in investment to save collapsing antibiotic pipelines. The partnership aims to bring between two and four new antibiotics to patients by 2030 and facilitate…

Korea Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on the future role of precision medicine, and the current hurdles impeding its widespread adoption.   The pandemic, while tragic, has…

Korea Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big Pharma in their oncology projects, and the potential to become a pan-Asian venture in the future.   It is very…

Belgium In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally can contribute to the rapid development of a safe and effective COVID-19 vaccine. Dr Hanon outlines the challenges inherent in…

USA Dr Brett Monia, co-founder and CEO of RNA therapeutics pioneer Ionis Pharmaceuticals, outlines the company’s extremely promising development pipeline, commercial partnerships with Big Pharma, and his ambitious strategy to launch ten or more products by 2025.   We have many programs currently in Phase III development. All these medicines are…

Coronavirus The BIO International Convention was held digitally in June 2020, bringing together over 7,000 participants from around the world. In an R&D-focused session titled “Whiplash! How Covid-19 Will Radically Change Biomedical R&D Across the Globe,” moderator Andy Marshall of Nature Biotechnology brought together experts in biotech, pharma innovation and research.…